Business UpdateJul 23, 2026, 04:52 PM
HeartSciences MyoVista wavECG FDA Review; Insights Gets Epic Designation
AI Summary
HeartSciences Inc. provided a business update in its 10-K filing, highlighting that its MyoVista Insights™ platform received Epic Toolbox designation in March 2026 and has secured commercial customer engagements. The company also confirmed that its MyoVista wavECG device was submitted to the FDA for 510(k) premarket clearance in December 2025, with the submission remaining under review. HeartSciences noted it will require additional funding to support working capital, continued development, and regulatory clearance for its products.
Key Highlights
- MyoVista Insights™ platform received Epic Toolbox designation in March 2026.
- MyoVista Insights™ released a significant version upgrade in March 2026 for broader deployment.
- HeartSciences announced commercial customer engagements for MyoVista Insights™.
- MyoVista wavECG device was submitted to the FDA for 510(k) premarket clearance in December 2025.
- FDA review for MyoVista wavECG device is ongoing with no assurance on timing or outcome.
- Company requires additional funding for working capital, development, and regulatory clearance.
- Aggregate market value of non-affiliate voting stock was approximately $10.4 million as of October 31, 2025.
- 3,899,491 shares of Common Stock were issued and outstanding as of July 20, 2026.
Price Impact
More from HSCS